Reneo Pharmaceuticals, Inc. (RPHM) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Irvine, CA, 미국. 현재 CEO는 Gregory J. Flesher.
RPHM 을(를) 보유 IPO 날짜 2021-04-08, 8 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $60.84M.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
